Nature Communications (Mar 2020)
Chromatin accessibility promotes hematopoietic and leukemia stem cell activity
- Lucia Cabal-Hierro,
- Peter van Galen,
- Miguel A. Prado,
- Kelly J. Higby,
- Katsuhiro Togami,
- Cody T. Mowery,
- Joao A. Paulo,
- Yingtian Xie,
- Paloma Cejas,
- Takashi Furusawa,
- Michael Bustin,
- Henry W. Long,
- David B. Sykes,
- Steven P. Gygi,
- Daniel Finley,
- Bradley E. Bernstein,
- Andrew A. Lane
Affiliations
- Lucia Cabal-Hierro
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Peter van Galen
- Broad Institute of Harvard and MIT
- Miguel A. Prado
- Department of Cell Biology, Harvard Medical School
- Kelly J. Higby
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Katsuhiro Togami
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Cody T. Mowery
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Joao A. Paulo
- Department of Cell Biology, Harvard Medical School
- Yingtian Xie
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Paloma Cejas
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- Takashi Furusawa
- Laboratory of Metabolism, National Cancer Institute
- Michael Bustin
- Laboratory of Metabolism, National Cancer Institute
- Henry W. Long
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- David B. Sykes
- Center for Regenerative Medicine, Massachusetts General Hospital
- Steven P. Gygi
- Department of Cell Biology, Harvard Medical School
- Daniel Finley
- Department of Cell Biology, Harvard Medical School
- Bradley E. Bernstein
- Broad Institute of Harvard and MIT
- Andrew A. Lane
- Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-020-15221-z
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 18
Abstract
Chromatin accessibility is a key mediator of gene expression and mutations in chromatin modifiers are frequently seen in cancers. Here, the authors show that the chromatin accessibility regulator HMGN1 - which is frequently mutated by amplification in leukemias - acts by blocking myeloid differentiation.
